Skip Ribbon Commands
Skip to main content
Sign In
Navigate Up

26416 Antithrombin Antigen, Plasma (ATTI)

Antithrombin Antigen, Plasma (ATTI)
Test Code: ATTISO
Synonyms/Keywords

Antithrombin III, Immunologic, Plasma

AT III Antigen/Immunologic

AT3 Antigen/Immunologic

Useful For

Assessing abnormal results of the antithrombin activity assay (ATTF / Antithrombin Activity, Plasma), which is recommended as the primary (screening) antithrombin assay

Diagnosing antithrombin deficiency, acquired or congenital, in conjunction with measurement of antithrombin activity

An adjunct in the diagnosis and management of carbohydrate-deficient glycoprotein syndromes

Specimen Requirements
Fasting RequiredSpecimen TypePreferred Container/TubeAcceptable Container/TubeSpecimen VolumeSpecimen Minimum Volume
(allows for 1 repeat)		Pediatric Minimum Volume
(no repeat)
​Preferred​Plasma Na Cit​Citrated Blue Top Tube (BTT)​​1 mL​0.5 mL​
Collection Processing Instructions

​If patient is being treated with heparin, this should be noted as heparin treatment may lower plasma antithrombin.

1. Centrifuge, remove plasma, and centrifuge plasma again.

2. Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or, ideally, < or =-40 degrees C.

Additional Information:

1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.

2. Each coagulation assay requested should have its own vial.

Specimen Stability Information
Specimen TypeTemperatureTime
​Plasma Na Cit​Frozen (preferred)​14 days
Rejection Criteria
Gross hemolysis
​Gross lipemia
​Gross icterus
Interference

Antithrombin antigen results are potentially affected by:

-Heparin (unfractionated or low-molecular-weight) >4 U/mL

-Hemoglobin >7 g/L

-Bilirubin >500 mg/L

-Lipemia; may lead to an over-estimation of the antithrombin antigen level

-Rheumatoid factor (RF) >800 IU/mL; may lead to overestimation of the antithrombin antigen level

-Anti-rabbit antibodies in certain subjects leads to aberrant results

-Heparin therapy may temporarily decrease plasma antithrombin antigen into the abnormal range

Performing Laboratory Information
Performing LocationDay(s) Test PerformedReport AvailableMethodology/Instrumentation
​Mayo Clinic Laboratories​Monday through Friday​1 to 4 days​Latex Immunoassay (LIA)
Reference Lab
Mayo Clinic Laboratories
Reference Range Information
Performing LocationReference Range
​Mayo Clinic Laboratories​Adults: 80-120%
Normal, full-term newborn infants may have decreased levels (> or =35-40%), which reach adult levels by 180 days postnatal.*
Healthy, premature infants (30-36 weeks gestation) may have decreased levels, which reach adult levels by 180 days postnatal.*
*See Pediatric Hemostasis References section in Coagulation Guidelines for Specimen Handling and Processing in Special Instructions.
Interpretation

Hereditary antithrombin deficiency is much less common than acquired deficiency. Diagnosis of hereditary deficiency requires clinical correlation, testing of both antithrombin activity and antithrombin antigen, and may be aided by repeated testing and by family studies. DNA-based diagnostic testing may be helpful, but is generally not readily available.

Acquired antithrombin deficiency may occur in association with a number of conditions (see Clinical Information). The clinical significance (thrombotic risk) of acquired antithrombin deficiency is not well established, but accumulating information suggests possible benefit of antithrombin replacement therapy in carefully selected situations.(4)

Increased antithrombin activity has no definite clinical significance.

Outreach CPTs
CPTModifier
(if needed)		QuantityDescriptionComments
​85301​​1​​
Synonyms/Keywords

Antithrombin III, Immunologic, Plasma

AT III Antigen/Immunologic

AT3 Antigen/Immunologic

Ordering Applications
Ordering ApplicationDescription
​COM​Antithrombin Antigen, Plasma (ATTI)
​Cerner​Antithrombin Antigen, Plasma (ATTI)
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting RequiredSpecimen TypePreferred Container/TubeAcceptable Container/TubeSpecimen VolumeSpecimen Minimum Volume
(allows for 1 repeat)		Pediatric Minimum Volume
(no repeat)
​Preferred​Plasma Na Cit​Citrated Blue Top Tube (BTT)​​1 mL​0.5 mL​
Collection Processing

​If patient is being treated with heparin, this should be noted as heparin treatment may lower plasma antithrombin.

1. Centrifuge, remove plasma, and centrifuge plasma again.

2. Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or, ideally, < or =-40 degrees C.

Additional Information:

1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.

2. Each coagulation assay requested should have its own vial.

Specimen Stability Information
Specimen TypeTemperatureTime
​Plasma Na Cit​Frozen (preferred)​14 days
Rejection Criteria
Gross hemolysis
​Gross lipemia
​Gross icterus
Interference

Antithrombin antigen results are potentially affected by:

-Heparin (unfractionated or low-molecular-weight) >4 U/mL

-Hemoglobin >7 g/L

-Bilirubin >500 mg/L

-Lipemia; may lead to an over-estimation of the antithrombin antigen level

-Rheumatoid factor (RF) >800 IU/mL; may lead to overestimation of the antithrombin antigen level

-Anti-rabbit antibodies in certain subjects leads to aberrant results

-Heparin therapy may temporarily decrease plasma antithrombin antigen into the abnormal range

Useful For

Assessing abnormal results of the antithrombin activity assay (ATTF / Antithrombin Activity, Plasma), which is recommended as the primary (screening) antithrombin assay

Diagnosing antithrombin deficiency, acquired or congenital, in conjunction with measurement of antithrombin activity

An adjunct in the diagnosis and management of carbohydrate-deficient glycoprotein syndromes

Reference Range Information
Performing LocationReference Range
​Mayo Clinic Laboratories​Adults: 80-120%
Normal, full-term newborn infants may have decreased levels (> or =35-40%), which reach adult levels by 180 days postnatal.*
Healthy, premature infants (30-36 weeks gestation) may have decreased levels, which reach adult levels by 180 days postnatal.*
*See Pediatric Hemostasis References section in Coagulation Guidelines for Specimen Handling and Processing in Special Instructions.
Interpretation

Hereditary antithrombin deficiency is much less common than acquired deficiency. Diagnosis of hereditary deficiency requires clinical correlation, testing of both antithrombin activity and antithrombin antigen, and may be aided by repeated testing and by family studies. DNA-based diagnostic testing may be helpful, but is generally not readily available.

Acquired antithrombin deficiency may occur in association with a number of conditions (see Clinical Information). The clinical significance (thrombotic risk) of acquired antithrombin deficiency is not well established, but accumulating information suggests possible benefit of antithrombin replacement therapy in carefully selected situations.(4)

Increased antithrombin activity has no definite clinical significance.

For more information visit:
Performing Laboratory Information
Performing LocationDay(s) Test PerformedReport AvailableMethodology/Instrumentation
​Mayo Clinic Laboratories​Monday through Friday​1 to 4 days​Latex Immunoassay (LIA)
Reference Lab
Mayo Clinic Laboratories
For billing questions, see Contacts
Outreach CPTs
CPTModifier
(if needed)		QuantityDescriptionComments
​85301​​1​​
For most current information refer to the Marshfield Laboratory online reference manual.